Objective: To explore the correlations between opalescence and molecular size, purity or aggregation tendency in the antibody formulation. Methods: Studied on the opalescence phenomena of various antibodies, including the influence of different concentrations, pH/buffer, excipients, as well as the influence of environmental factors such as temperature, light, freeze-thaw and agitation, and the correlations had been analyzed between opalescence and molecular size, purity (aggregation), KD or Tagg. Results: The degree of antibody opalescence was positively correlated with the molecular size, the deepening of the opalescence indicated that the molecular size was increased and the more tendency of molecular aggregation. For example, the opalescence of C molecule obviously enhanced under high temperature, and the result of turbidity changed from 3.3 NTU to 13.6 NTU, the molecular size changed from 13.1 nm to 40.6 nm, and the KD changed from positive to negative. The Tagg changed from 59.6 ℃ to below 50 ℃. Conclusion: The opalescence can be affected by buffer system, pH, excipients and ambient temperature, the degree of opalescence increased, indicating the stability become worse and the molecules prone to aggregate. This study provides important reference for the analysis and evaluation of opalescence in the antibody formulation development.
[1] 李萌, 于传飞, 王兰, 等. 重组单抗药物质控中物理检查的有关问题探讨[J]. 药物分析杂志, 2015, 35(11):2036
LI M, YU CF, WANG L, et al. Discussion on issues related to physical tests in quality control of Mabs[J]. Chin J Pharm Anal, 2015, 35(11):2036
[2] NINA U, ANTONIO F, ULRIKE H. Investigation of tryptophan-related yellowing in parenteral amino acid solution: development of a stability-indicating method and assessment of degradation products in pharmaceutical formulations[J]. J Pharm Biomed Anal, 2020, 177: 112839
[3] DU C, XU JL, SONG HT, et al. Mechanisms of color formation in drug substance and mitigation strategies for the manufacture and storage of therapeutic proteins produced using mammalian cell culture[J]. Process Biochem, 2019, 86: 127
[4] GREGORY VB, GURUSAMY B, NARESH C, et al. Probing the tryptophan environment in therapeutic proteins: implications for higher order structure on tryptophan oxidation[J]. J Pharm Sci, 2019, 108(6):1944
[5] MAHLER HC, MATTER A. Solubility, Opalescence, and Particulate Matter[M]//Challenges in Protein Product Development. Switzerland: AAPS, 2018: 125
[6] 耿志旺, 何兰, 张启明, 等. 纳米药物粒度分析方法[J]. 药学学报, 2012, 47(7):856
GENG ZW, HE L, ZHANG QM, et al. Methods for grain size analysis of nanomedicines[J]. Acta Pharm Sin, 2012, 47(7):856
[7] 郭莎, 张峰, 于传飞, 等. 单抗制剂多维度稳定性分析[J]. 中国药学杂志, 2021, 56(15):95
GUO S, ZHANG F, YU CF, et al. Multi-dimensional stability analysis of monoclonal antibodies[J]. Chin Pharm J, 2021, 56(15):95
[8] JARASCH A, HANS K, JOERG TR, et al. Developability assessment during the selection of novel therapeutic antibodies[J]. J Pharm Sci, 2015, 104(6):1885
[9] CHENG WQ, JOSHI SB, JAIN NK. Linking the solution viscosity of an IgG2 monoclonal antibody to its structure as a function of pH and temperature[J]. J Pharm Sci, 2013, 102(12):4291
[10] KINGSBURY JS, LANTZ MM, SAINI A, et al. Characterization of opalescence in low volume monoclonal antibody solutions enabled by microscale nephelometry[J]. J Pharm Sci, 2021, 110(9):3176
[11] SUKUMAR M, DOYLE BL, COMBS JL, et al. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association[J]. Pharm Res, 2004, 21(7):1087
[12] SALINAS BA, SATHISH HA, BISHOP SM, et al. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation[J]. J Pharm Sci, 2010, 99(1):82
[13] WANG N, HU BH, IONESCU R, et al. Opalescence of an IgG1 monoclonal antibody formulation is mediated by ionic strength and excipients[J]. Biopharm Int, 2009, 22(4):36
[14] MOELBERT S, NORMAND B, PAOLO DLR. Kosmotropes and chaotropes: modelling preferential exclusion, binding and aggregate stability[J]. Biophys Chem, 2004, 112(1):45
[15] REZA E, HAYES DB, ARUN P, et al. A systematic multi technique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies[J]. J Pharm Sci, 2013, 102(9):3089
[16] 邱晓, 罗建辉. 重组单克隆抗体药物制剂处方的作用及相关审评要点[J]. 中国新药杂志, 2019, 28(16):1947
QIU X, LUO JH. Roles of the components of product formulation of monoclonal antibodies and the points to consider for drug evaluation[J]. Chin J New Drugs, 2019, 28(16):1947
[17] SUDRIK CM, THERESA C, NEIL M, et al. Understanding the role of preferential exclusion of sugars and polyols from native state IgG1 monoclonal antibodies and its effect on aggregation and reversible self-association[J]. Pharm Res, 2019, 36(8):109
[18] 王传杰, 冯健男, 王晶. 单克隆抗体药物稳定性影响因素及优化策略[J]. 中国免疫学杂志, 2021, 17(37):2154
WANG CJ, FENG JN, WANG J. Influence factors and optimization strategy in stability of monoclonal antibody drugs[J]. Chin J Immunol, 2021, 17(37):2154
[19] JOSHI A, NAND K. Macromolecular crowding and preferential exclusion counteract the effect of protein denaturant: biophysical aspects[J]. J Mol Liq, 2022, 360: 119429
[20] SHOGO O, SUGURU N, YOSHITAKA N, et al. Arginine and its derivatives suppress the opalescence of an antibody solution[J]. J Pharm Sci, 2022, 111(4):1126
[21] NAKAUCHI Y, NISHINAMI S, MURAKAMI Y. Opalescence arising from network assembly in antibody solution[J]. Mol Pharm, 2022, 19(4):1160
[22] RAUT AS, KALONIA DS. Opalescence in monoclonal antibody solutions and its correlation with intermolecular interactions in dilute and concentrated solutions[J]. J Pharm Sci, 2015, 104(4):1263
